胸腺肽a1联合抗病毒药治疗肾移植术后巨细胞病毒肺炎

Combination therapy of thymosin a1 and antiviral drugs in kidney transplant recipients with cytomegalovirus pneumonia

目的研究胸腺肽a1对肾移植术后巨细胞病毒(CMV)肺炎的治疗效果和不良反应。方法肾移植术后CMV肺炎患者46例分为两组,组Ⅰ单独使用抗病毒药更昔洛韦,组Ⅱ联合应用胸腺肽a1和抗病毒药。结果46例患者总存活率56.52%(26/46),组Ⅱ存活率72.73%(16/22)明显高于组Ⅰ患者的41.67%(10/24)(P<0.05),两组各有1例发生急性排斥反应。结论胸腺肽a1联合抗病毒药可提高CMV肺炎的治愈率,是安全有效的抗CMV病毒肺炎的疗法。

[Objctive] To study the therapeutic effect and side effect of thymosin al on cytomegalovirus pneumonia in kidney transplant recipients. [Methods] 46 patients with cytomegalovirus pneumonia following kidney transplantation were divided into two groups. Group Ⅰwas （n =24） administered with ganciclovir intravenously and group Ⅱ （n =22）eras administered with thymosin alby subcutaneous injection and combined with ganciclovir. [Results] Among 46 patients, the survival rate was 56.52%（26/46）. The survival rate of group Ⅱ was higher than that of group Ⅰ and there was significant diffcrence （72,73% vs 41.67%, P 〈0.05）. 1 patient in each group developed acute rejection. No obvious side effects were observed. [Conclusion] Thymosin al combined with antiviral drugs may improve the survival rate of patients with CMV pneumonia and it is safe and effective in the treatment of CMV pneumonia.